Positive data announced from the pivotal part 2 of the SUNFISH trial that evaluated the safety and efficacy of risdiplam in adult and pediatric patients with Type 2 or Type 3 SMA.
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
Patients with Parkinson disease (PD) who use inappropriate antipsychotics may be at an increased risk for pneumonia compared with patients with PD who use more appropriate atypical antipsychotics.
The Food and Drug Administration (FDA) has placed a partial hold on clinical trials for the intrathecal administration of AVXS-101 (AveXis, a Novartis Company) in patients with spinal muscular atrophy (SMA) Type 2.
Early-stage Alzheimer disease seems to put households at risk for large adverse changes in liquid assets and may reduce net wealth.
Former soccer players have an increased risk for mortality from neurodegenerative diseases.
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
Compared with the general population, patients with bipolar disorder (BD) have an increased risk of developing idiopathic Parkinson disease (PD), study results published in JAMA Neurology suggest. Published studies that included data on the risk for PD in patients with BD vs the general population without BD were included in a systematic review. A total…
Company claimed their CBD products can be used to treat a variety of conditions and diseases including teething pain and earaches in infants, skin problems, autism, ADHD, Parkinson disease, and Alzheimer disease, among others.
Compared with placebo, high dose aducanumab was associated with significant reduction of clinical decline in patients with early Alzheimer disease, as measured by the change from baseline in Clinical Dementia Rating-Sum of Boxes score at 78 weeks.